Similar articles

• BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.

  Rusakiewicz S, Madrigal A, Travers P, Dodi AI. Rusakiewicz S, et al. Cancer Immunol Immunother. 2009 Sep;58(9):1449-57. doi: 10.1007/s00262-009-0703-x. Epub 2009 Apr 10. Cancer Immunol Immunother. 2009. PMID: 19360407 Free PMC article.
• HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.

  Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M, van Biezen JH, Hermans J, Willemze R, Niederwieser D. Posthuma EF, et al. Blood. 1999 Jun 1;93(11):3863-5. Blood. 1999. PMID: 10339494
• Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.

  Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G. Volpe G, et al. Cancer Res. 2007 Jun 1;67(11):5300-7. doi: 10.1158/0008-5472.CAN-06-3737. Cancer Res. 2007. PMID: 17545610
• Chronic myeloid leukemia as an immunological target.

  Lim SH, Coleman S. Lim SH, et al. Am J Hematol. 1997 Jan;54(1):61-7. doi: 10.1002/(sici)1096-8652(199701)54:1<61::aid-ajh9>3.0.co;2-2. Am J Hematol. 1997. PMID: 8980262 Review.
• BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.

  Clark RE, Christmas SE. Clark RE, et al. Leuk Lymphoma. 2001 Sep-Oct;42(5):871-80. doi: 10.3109/10428190109097706. Leuk Lymphoma. 2001. PMID: 11697642 Review.